Understanding and targeting cancer stem cells： therapeutic implications and challenges
Cancer stem cells （CSCs） have been identified as rare cell populations in many cancers, including leukemia and solid tumors. Accumulating evidence has suggested that CSCs are capable of self-renewal and differentiation into various types of cancer cells. Aberrant regulation of gene expression and so...
Saved in:
| Published in | Acta pharmacologica Sinica Vol. 34; no. 6; pp. 732 - 740 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.06.2013
Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Cancer stem cells （CSCs） have been identified as rare cell populations in many cancers, including leukemia and solid tumors. Accumulating evidence has suggested that CSCs are capable of self-renewal and differentiation into various types of cancer cells. Aberrant regulation of gene expression and some signaling pathways has been observed in CSCs compared to other tumor cells. CSCs are thought to be responsible for cancer initiation, progression, metastasis, recurrence and drug resistance. The CSC hypothesis has recently attracted much attention due to the potential for discovery and development of CSC-related therapies and the identification of key molecules involved in controlling the unique properties of CSC populations. Over the past several years, a tremendous amount of effort has been invested in the development of new drugs, such as nanomedicines, that can take advantage of the ＂Achilles＇ heel＂ of CSCs by targeting cell-surface molecular markers or various signaling pathways. Novel compounds and therapeutic strategies that selectively target CSCs have been identified, some of which have been evaluated in preclinical and clinical studies. In this article, we review new findings related to the investigation of the CSC hypothesis, and discuss the crucial pathways involved in regulating the development of CSC populations and the advances in studies of drug resistance. In addition, we review new CSC-targeted therapeutic strategies aiming to eradicate malignancies. |
|---|---|
| AbstractList | Cancer stem cells (CSCs) have been identified as rare cell populations in many cancers, including leukemia and solid tumors. Accumulating evidence has suggested that CSCs are capable of self-renewal and differentiation into various types of cancer cells. Aberrant regulation of gene expression and some signaling pathways has been observed in CSCs compared to other tumor cells. CSCs are thought to be responsible for cancer initiation, progression, metastasis, recurrence and drug resistance. The CSC hypothesis has recently attracted much attention due to the potential for discovery and development of CSC-related therapies and the identification of key molecules involved in controlling the unique properties of CSC populations. Over the past several years, a tremendous amount of effort has been invested in the development of new drugs, such as nanomedicines, that can take advantage of the “Achilles' heel” of CSCs by targeting cell-surface molecular markers or various signaling pathways. Novel compounds and therapeutic strategies that selectively target CSCs have been identified, some of which have been evaluated in preclinical and clinical studies. In this article, we review new findings related to the investigation of the CSC hypothesis, and discuss the crucial pathways involved in regulating the development of CSC populations and the advances in studies of drug resistance. In addition, we review new CSC-targeted therapeutic strategies aiming to eradicate malignancies. Cancer stem cells (CSCs) have been identified as rare cell populations in many cancers, including leukemia and solid tumors. Accumulating evidence has suggested that CSCs are capable of self-renewal and differentiation into various types of cancer cells. Aberrant regulation of gene expression and some signaling pathways has been observed in CSCs compared to other tumor cells. CSCs are thought to be responsible for cancer initiation, progression, metastasis, recurrence and drug resistance. The CSC hypothesis has recently attracted much attention due to the potential for discovery and development of CSC-related therapies and the identification of key molecules involved in controlling the unique properties of CSC populations. Over the past several years, a tremendous amount of effort has been invested in the development of new drugs, such as nanomedicines, that can take advantage of the "Achilles' heel" of CSCs by targeting cell-surface molecular markers or various signaling pathways. Novel compounds and therapeutic strategies that selectively target CSCs have been identified, some of which have been evaluated in preclinical and clinical studies. In this article, we review new findings related to the investigation of the CSC hypothesis, and discuss the crucial pathways involved in regulating the development of CSC populations and the advances in studies of drug resistance. In addition, we review new CSC-targeted therapeutic strategies aiming to eradicate malignancies.Cancer stem cells (CSCs) have been identified as rare cell populations in many cancers, including leukemia and solid tumors. Accumulating evidence has suggested that CSCs are capable of self-renewal and differentiation into various types of cancer cells. Aberrant regulation of gene expression and some signaling pathways has been observed in CSCs compared to other tumor cells. CSCs are thought to be responsible for cancer initiation, progression, metastasis, recurrence and drug resistance. The CSC hypothesis has recently attracted much attention due to the potential for discovery and development of CSC-related therapies and the identification of key molecules involved in controlling the unique properties of CSC populations. Over the past several years, a tremendous amount of effort has been invested in the development of new drugs, such as nanomedicines, that can take advantage of the "Achilles' heel" of CSCs by targeting cell-surface molecular markers or various signaling pathways. Novel compounds and therapeutic strategies that selectively target CSCs have been identified, some of which have been evaluated in preclinical and clinical studies. In this article, we review new findings related to the investigation of the CSC hypothesis, and discuss the crucial pathways involved in regulating the development of CSC populations and the advances in studies of drug resistance. In addition, we review new CSC-targeted therapeutic strategies aiming to eradicate malignancies. Cancer stem cells （CSCs） have been identified as rare cell populations in many cancers, including leukemia and solid tumors. Accumulating evidence has suggested that CSCs are capable of self-renewal and differentiation into various types of cancer cells. Aberrant regulation of gene expression and some signaling pathways has been observed in CSCs compared to other tumor cells. CSCs are thought to be responsible for cancer initiation, progression, metastasis, recurrence and drug resistance. The CSC hypothesis has recently attracted much attention due to the potential for discovery and development of CSC-related therapies and the identification of key molecules involved in controlling the unique properties of CSC populations. Over the past several years, a tremendous amount of effort has been invested in the development of new drugs, such as nanomedicines, that can take advantage of the ＂Achilles＇ heel＂ of CSCs by targeting cell-surface molecular markers or various signaling pathways. Novel compounds and therapeutic strategies that selectively target CSCs have been identified, some of which have been evaluated in preclinical and clinical studies. In this article, we review new findings related to the investigation of the CSC hypothesis, and discuss the crucial pathways involved in regulating the development of CSC populations and the advances in studies of drug resistance. In addition, we review new CSC-targeted therapeutic strategies aiming to eradicate malignancies. |
| Author | Ke CHEN Ying-hui HUANG Ji-long CHEN |
| AuthorAffiliation | CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences （CAS）, Beijing 100101, China China-Japan Union Hospital of Jilin University, Changchun 130033, China College of Animal Science, Fujian Agriculture and Forestry University, Fuzhou 350002, China |
| Author_xml | – sequence: 1 givenname: Ke surname: Chen fullname: Chen, Ke organization: CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS) – sequence: 2 givenname: Ying-hui surname: Huang fullname: Huang, Ying-hui organization: China-Japan Union Hospital of Jilin University – sequence: 3 givenname: Ji-long surname: Chen fullname: Chen, Ji-long email: chenjl@im.ac.cn organization: CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), College of Animal Science, Fujian Agriculture and Forestry University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23685952$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkcuKFDEUhoOMOBdduZcSN4JWm3sqG0EGbzDgxgF3IZ06XZ2hKlWTpARfxWfxnXwFU9NtMw4Krk5Cvv_kP-c_RUdhDIDQY4JXBLPmlZ3SimLCVlTdQydEcVErKvhROUtFao4bdoxOU7rCmFFG9AN0TJlshBb0BH25DC3ElG1ofeiqUqpsYwd5uTkbHMQqZRgqB32ffv74XuUtRDvBnL2r_DD13tnsx5ButG5r-x5CB-khur-xfYJH-3qGLt-9_Xz-ob749P7j-ZuL2glFck3WllmMCbZMUcBOg2iJkFKuNw0XGLeAFW41JdxuCGjrBHcNBlBCaMWYY2fo9a7vNK8HaB2EHG1vpugHG7-Z0Xrz50vwW9ONXw2TZVNElgbP9w3ieD1DymbwaZnWBhjnZAjTWpOyRPEfqBQCN4Tigj67g16NcwxlEwvFlVa8IYV6ctv8wfXvfArwYge4OKYUYXNACDZL-qakb5b0DVWFJndo5_NNOmVy3_9D83KnSaVzCS7eMvpX_On-i-0YuuuiODjiknDJG8l-ATkVzfo |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0307943 crossref_primary_10_1007_s12672_024_01262_z crossref_primary_10_1186_s13000_019_0903_4 crossref_primary_10_1186_s12943_016_0574_7 crossref_primary_10_3390_biom11081074 crossref_primary_10_1038_s41368_019_0069_7 crossref_primary_10_1038_s41419_020_02780_8 crossref_primary_10_1016_j_ceca_2019_05_006 crossref_primary_10_18632_oncotarget_24591 crossref_primary_10_54005_geneltip_1053439 crossref_primary_10_1038_leu_2014_244 crossref_primary_10_1016_j_jmb_2016_03_003 crossref_primary_10_1089_omi_2020_0122 crossref_primary_10_1177_1534735419848047 crossref_primary_10_1186_s12859_016_0997_6 crossref_primary_10_3390_ijms20051027 crossref_primary_10_1016_j_bioorg_2020_104574 crossref_primary_10_1016_j_jconrel_2015_09_067 crossref_primary_10_1186_s12935_018_0654_4 crossref_primary_10_3390_cimb46060323 crossref_primary_10_3390_ijms23094814 crossref_primary_10_1371_journal_pone_0225898 crossref_primary_10_1016_j_semcdb_2016_07_020 crossref_primary_10_1038_s41598_017_05086_6 crossref_primary_10_3389_fendo_2021_689532 crossref_primary_10_1016_j_addr_2021_113909 crossref_primary_10_1002_jbio_201500282 crossref_primary_10_1517_14740338_2016_1161020 crossref_primary_10_1016_j_biopha_2020_110623 crossref_primary_10_3389_fphar_2017_00051 crossref_primary_10_1007_s12038_016_9624_y crossref_primary_10_3390_cells11213492 crossref_primary_10_1016_j_bbrc_2015_12_066 crossref_primary_10_1177_1934578X20982108 crossref_primary_10_1016_j_envres_2023_116506 crossref_primary_10_1016_j_biocel_2017_07_003 crossref_primary_10_1038_ncomms10180 crossref_primary_10_1080_01635581_2020_1795695 crossref_primary_10_1155_2019_7462513 crossref_primary_10_1038_s41467_024_53771_8 crossref_primary_10_1634_theoncologist_2019_0517 crossref_primary_10_1080_15384047_2019_1599660 crossref_primary_10_1016_j_addr_2017_07_013 crossref_primary_10_1155_2018_5416923 crossref_primary_10_1016_j_tiv_2016_05_015 crossref_primary_10_2217_bmm_15_85 crossref_primary_10_1002_stem_2579 crossref_primary_10_1038_ncomms15870 crossref_primary_10_1186_s12918_018_0525_6 crossref_primary_10_3390_molecules25235776 crossref_primary_10_3390_genes14091735 crossref_primary_10_3390_ijms252212102 crossref_primary_10_1186_s12943_019_0988_0 crossref_primary_10_1002_jcp_30599 crossref_primary_10_1016_j_phrs_2016_11_017 crossref_primary_10_1007_s13277_015_4007_9 crossref_primary_10_1021_ab500084g crossref_primary_10_15690_vramn833 crossref_primary_10_1053_j_seminoncol_2015_01_001 crossref_primary_10_1074_jbc_RA119_010252 crossref_primary_10_3892_mmr_2020_11073 crossref_primary_10_1155_2019_9296439 crossref_primary_10_3390_ijms19082188 crossref_primary_10_1016_j_actbio_2016_10_009 crossref_primary_10_1016_j_biopha_2023_114502 crossref_primary_10_1073_pnas_2002499117 crossref_primary_10_2174_0929867330666230503144619 crossref_primary_10_3390_ijms231810663 crossref_primary_10_1016_j_biomaterials_2016_06_038 crossref_primary_10_1016_j_bbrc_2018_01_164 crossref_primary_10_18632_oncotarget_13141 crossref_primary_10_2217_fon_2023_0907 crossref_primary_10_1136_jitc_2023_006677 crossref_primary_10_18632_oncotarget_5812 crossref_primary_10_1016_j_apsb_2020_09_016 crossref_primary_10_1002_ijc_32728 crossref_primary_10_1016_j_bbamcr_2017_06_015 crossref_primary_10_3390_ijms24087621 crossref_primary_10_3390_cancers11101527 crossref_primary_10_3390_biology13070521 crossref_primary_10_1101_gad_329771_119 crossref_primary_10_1007_s12015_017_9757_x crossref_primary_10_1097_CAD_0000000000000659 crossref_primary_10_1186_1471_2407_14_591 crossref_primary_10_1158_0008_5472_CAN_15_2664 crossref_primary_10_1016_j_critrevonc_2016_08_006 crossref_primary_10_1080_14737159_2023_2298681 crossref_primary_10_3389_fcell_2022_993915 crossref_primary_10_1016_j_intimp_2024_112306 crossref_primary_10_1016_j_jconrel_2017_11_026 crossref_primary_10_1080_20477724_2015_1103504 crossref_primary_10_1002_iub_1426 crossref_primary_10_1042_BCJ20170164 crossref_primary_10_1002_chem_201803521 crossref_primary_10_1186_s13148_021_01107_4 crossref_primary_10_1002_1878_0261_12979 crossref_primary_10_1080_21655979_2020_1765500 crossref_primary_10_1080_23808993_2019_1567266 crossref_primary_10_1016_j_prp_2020_153226 crossref_primary_10_1093_carcin_bgx040 crossref_primary_10_18632_oncotarget_4725 crossref_primary_10_1002_chem_201701939 crossref_primary_10_1080_07391102_2023_2218936 crossref_primary_10_1371_journal_pone_0132306 crossref_primary_10_1158_0008_5472_CAN_19_3232 crossref_primary_10_3390_cancers8010005 crossref_primary_10_18632_oncotarget_25014 crossref_primary_10_34172_bi_2022_23336 crossref_primary_10_3390_ma12060909 crossref_primary_10_1002_mog2_62 crossref_primary_10_3390_molecules24050899 crossref_primary_10_3892_ijo_2015_2961 crossref_primary_10_3892_ijo_2016_3782 crossref_primary_10_3390_ijms21072327 crossref_primary_10_1016_j_semcancer_2018_09_003 crossref_primary_10_1038_srep10194 crossref_primary_10_3389_fbioe_2021_691091 crossref_primary_10_1007_s10529_017_2303_8 crossref_primary_10_3389_fcell_2020_00442 crossref_primary_10_1186_s12935_018_0650_8 crossref_primary_10_3389_fmolb_2021_600373 crossref_primary_10_3389_fonc_2022_935715 crossref_primary_10_3892_or_2015_3950 crossref_primary_10_1007_s12015_019_09887_2 crossref_primary_10_3390_cancers14143524 crossref_primary_10_18632_oncotarget_7113 crossref_primary_10_1080_1061186X_2019_1703188 crossref_primary_10_1155_2013_782581 crossref_primary_10_1016_j_biopha_2020_110909 crossref_primary_10_1016_j_dld_2018_08_019 crossref_primary_10_1002_mco2_176 crossref_primary_10_1080_21691401_2017_1366337 crossref_primary_10_1097_MD_0000000000004765 crossref_primary_10_1007_s00441_018_2928_5 crossref_primary_10_1186_s12917_018_1624_8 crossref_primary_10_1186_s13028_016_0268_6 crossref_primary_10_1002_cam4_6520 crossref_primary_10_1038_pcan_2015_35 crossref_primary_10_1038_cti_2014_16 crossref_primary_10_23868_gc120458 crossref_primary_10_3390_cancers7030851 crossref_primary_10_1016_j_semcancer_2017_04_006 crossref_primary_10_1002_smll_202006009 crossref_primary_10_3390_ijms21113742 crossref_primary_10_1016_j_biopha_2021_112260 crossref_primary_10_1016_j_fct_2014_11_004 crossref_primary_10_1039_C8DT04706E crossref_primary_10_3390_cells9102281 crossref_primary_10_4161_2162402X_2014_990767 crossref_primary_10_31857_S0320972523070102 crossref_primary_10_3390_cancers14153786 crossref_primary_10_1155_2015_454837 crossref_primary_10_3892_ol_2015_2918 crossref_primary_10_1007_s00432_023_05202_2 crossref_primary_10_1097_MD_0000000000004766 crossref_primary_10_1016_j_semcancer_2018_06_006 crossref_primary_10_1038_onc_2016_320 crossref_primary_10_1038_aps_2013_72 crossref_primary_10_1007_s12272_015_0628_1 crossref_primary_10_18632_oncotarget_19881 crossref_primary_10_3390_cancers16183134 crossref_primary_10_1186_s40360_017_0118_9 crossref_primary_10_1038_nm_3434 crossref_primary_10_1016_j_biopha_2024_116365 crossref_primary_10_3390_ijms17060893 crossref_primary_10_1155_2020_4736091 crossref_primary_10_1615_CritRevOncog_2022047207 crossref_primary_10_18632_oncotarget_6176 crossref_primary_10_2174_1875318301808010009 crossref_primary_10_3390_cancers11060867 crossref_primary_10_3389_fimmu_2016_00270 crossref_primary_10_1134_S0006297923070106 crossref_primary_10_3892_ol_2017_6756 crossref_primary_10_1038_s41392_024_01888_z crossref_primary_10_3748_wjg_v27_i15_1578 crossref_primary_10_1080_2162402X_2017_1404212 crossref_primary_10_2139_ssrn_3897705 crossref_primary_10_1186_s12885_018_4758_y crossref_primary_10_1038_s41598_017_14364_2 crossref_primary_10_1007_s00401_017_1757_z crossref_primary_10_1016_j_jbior_2014_07_002 crossref_primary_10_2174_1381612826666200403131514 crossref_primary_10_1039_C6MD00391E crossref_primary_10_1007_s10616_017_0112_5 crossref_primary_10_1038_s41598_017_14506_6 crossref_primary_10_2174_1574888X13666180821155701 crossref_primary_10_1002_anie_201710910 crossref_primary_10_1039_C5AN01858G crossref_primary_10_1186_s12943_016_0555_x crossref_primary_10_1111_jcmm_14689 crossref_primary_10_1155_2017_5619472 crossref_primary_10_1177_1756287219875576 crossref_primary_10_1371_journal_pone_0176851 crossref_primary_10_1016_j_apsb_2021_09_030 crossref_primary_10_3390_cancers15092653 crossref_primary_10_3389_fphar_2016_00244 crossref_primary_10_1021_ja508808v crossref_primary_10_1080_10667857_2021_1924436 crossref_primary_10_2139_ssrn_3991817 crossref_primary_10_1016_j_omton_2024_200905 crossref_primary_10_1016_j_canlet_2019_01_021 crossref_primary_10_18632_oncotarget_22705 crossref_primary_10_1038_ncb3434 crossref_primary_10_1517_17425247_2015_998648 crossref_primary_10_3390_cells7080107 crossref_primary_10_1089_biores_2014_0035 crossref_primary_10_3390_ncrna8060080 crossref_primary_10_1002_cbic_201600368 crossref_primary_10_3390_cells12232713 crossref_primary_10_3390_ijms22073756 crossref_primary_10_4252_wjsc_v6_i5_606 crossref_primary_10_3390_pharmaceutics15122763 crossref_primary_10_1021_acsmedchemlett_8b00323 crossref_primary_10_1016_j_snb_2022_131655 crossref_primary_10_3390_ijms21197379 crossref_primary_10_3892_ol_2019_10560 crossref_primary_10_1039_C8RA04078H crossref_primary_10_1186_s13046_016_0415_y crossref_primary_10_1016_j_nimb_2018_12_005 crossref_primary_10_1080_1354750X_2022_2157875 crossref_primary_10_1093_glycob_cwv088 crossref_primary_10_1177_1010428317734691 crossref_primary_10_1002_ijc_32123 crossref_primary_10_1016_j_drudis_2017_04_005 crossref_primary_10_1111_1440_1681_12693 crossref_primary_10_1093_bib_bbv053 crossref_primary_10_1007_s12032_022_01871_0 crossref_primary_10_1016_j_molstruc_2022_132750 crossref_primary_10_1038_s41419_024_06717_3 crossref_primary_10_1016_j_pharmthera_2017_08_009 crossref_primary_10_3109_09553002_2014_892229 crossref_primary_10_3892_mmr_2015_4161 crossref_primary_10_1007_s40336_021_00444_x crossref_primary_10_1016_j_ejps_2019_105072 crossref_primary_10_1007_s11418_015_0923_7 crossref_primary_10_1007_s13277_015_4155_y crossref_primary_10_1080_17425255_2016_1179280 crossref_primary_10_1111_vco_12917 crossref_primary_10_14348_molcells_2017_0089 crossref_primary_10_2217_nnm_2016_0388 crossref_primary_10_18632_oncotarget_5477 crossref_primary_10_1038_jid_2015_145 crossref_primary_10_1038_s41598_019_49853_z crossref_primary_10_2174_0115733947253349231027043858 crossref_primary_10_17116_patol201678247_54 crossref_primary_10_1186_s12885_015_1463_y crossref_primary_10_1016_j_biomaterials_2015_09_037 crossref_primary_10_1186_1476_4598_13_262 crossref_primary_10_1038_bjc_2013_691 crossref_primary_10_1038_cddis_2016_157 crossref_primary_10_1038_s41598_018_27204_8 crossref_primary_10_4252_wjsc_v8_i10_316 crossref_primary_10_1371_journal_pone_0146052 crossref_primary_10_18632_oncotarget_7429 crossref_primary_10_1016_j_jconrel_2018_02_040 crossref_primary_10_18632_oncotarget_9602 crossref_primary_10_1021_acs_jmedchem_5b01690 crossref_primary_10_1080_13543776_2017_1325465 crossref_primary_10_1186_s12943_017_0601_3 crossref_primary_10_1186_s13046_023_02931_7 crossref_primary_10_1186_s12943_018_0858_1 crossref_primary_10_1016_j_jconrel_2014_11_011 crossref_primary_10_1080_14756366_2017_1419221 crossref_primary_10_1177_1010428317706913 crossref_primary_10_1080_23808993_2016_1241128 crossref_primary_10_2174_1574888X13666181002152247 crossref_primary_10_3892_ol_2022_13239 crossref_primary_10_1002_1878_0261_13180 crossref_primary_10_14348_molcells_2016_0310 crossref_primary_10_1371_journal_pone_0150407 crossref_primary_10_3389_fonc_2016_00138 crossref_primary_10_3389_fcell_2021_666515 crossref_primary_10_1016_j_ejmech_2017_12_061 crossref_primary_10_3390_cancers15051621 crossref_primary_10_1016_j_gendis_2015_04_001 crossref_primary_10_3390_ijms23137131 crossref_primary_10_1016_j_drudis_2016_03_004 crossref_primary_10_1186_s13046_020_1530_3 crossref_primary_10_1016_j_biomaterials_2015_07_012 crossref_primary_10_1016_j_ejphar_2022_175412 crossref_primary_10_3389_fmolb_2017_00052 crossref_primary_10_1038_s41388_018_0674_5 crossref_primary_10_1016_j_bbadis_2019_02_019 crossref_primary_10_1111_jfbc_13868 crossref_primary_10_1016_j_cca_2020_08_016 crossref_primary_10_1038_cddis_2015_313 crossref_primary_10_1016_j_nano_2016_10_005 crossref_primary_10_1016_j_hermed_2020_100339 crossref_primary_10_3390_md18100498 crossref_primary_10_1002_anbr_202100017 crossref_primary_10_1155_2016_6475624 crossref_primary_10_1158_1078_0432_CCR_17_1952 crossref_primary_10_1371_journal_pone_0169230 crossref_primary_10_3389_fcell_2019_00229 crossref_primary_10_1158_0008_5472_CAN_17_2994 crossref_primary_10_3390_ncrna1010069 crossref_primary_10_1016_j_cmet_2020_10_005 crossref_primary_10_1016_j_biocel_2019_01_015 crossref_primary_10_1016_j_celrep_2023_113245 crossref_primary_10_1098_rsos_210148 crossref_primary_10_1007_s12032_024_02347_z crossref_primary_10_1007_s40778_016_0036_6 crossref_primary_10_3389_fmolb_2023_1297611 crossref_primary_10_3389_fphar_2022_874510 crossref_primary_10_3892_ol_2017_7014 crossref_primary_10_2174_1871520622666220901101204 crossref_primary_10_1002_cmdc_201800100 crossref_primary_10_3390_inorganics5010012 crossref_primary_10_2217_pme_2020_0099 crossref_primary_10_3390_pharmaceutics12080707 crossref_primary_10_1016_j_ejmech_2017_08_069 crossref_primary_10_1186_s12940_020_00670_2 crossref_primary_10_1158_0008_5472_CAN_16_1911 crossref_primary_10_3389_fmolb_2020_00079 crossref_primary_10_1038_s41598_018_35619_6 crossref_primary_10_1007_s10555_020_09930_6 crossref_primary_10_19161_etd_790394 crossref_primary_10_1002_ange_201710910 crossref_primary_10_1016_j_csbj_2021_04_006 crossref_primary_10_1039_C6MD00328A crossref_primary_10_3390_cancers11111678 crossref_primary_10_1016_j_biopha_2021_111815 crossref_primary_10_32725_jab_2021_019 crossref_primary_10_1186_s12943_015_0417_y crossref_primary_10_3390_ijms19071939 crossref_primary_10_3389_fonc_2019_00226 crossref_primary_10_1007_s00210_018_1479_3 crossref_primary_10_1016_j_jnci_2018_04_002 crossref_primary_10_1016_j_oraloncology_2016_10_008 crossref_primary_10_1016_j_jconrel_2021_08_027 crossref_primary_10_18632_oncotarget_21145 crossref_primary_10_1007_s12072_014_9539_3 crossref_primary_10_3892_or_2015_4371 crossref_primary_10_1186_s12885_018_4792_9 crossref_primary_10_3390_cancers15123110 crossref_primary_10_1002_bkcs_12072 crossref_primary_10_3892_ol_2014_2714 crossref_primary_10_1038_onc_2014_172 crossref_primary_10_1016_j_ejphar_2018_02_004 crossref_primary_10_1039_C8TB03165G crossref_primary_10_3390_cancers13143596 crossref_primary_10_1186_s12906_019_2685_3 crossref_primary_10_1186_s13630_016_0035_3 crossref_primary_10_15430_JCP_2014_19_2_89 crossref_primary_10_1016_j_tips_2017_06_005 crossref_primary_10_1016_j_biopha_2023_114505 crossref_primary_10_1007_s40203_024_00199_z crossref_primary_10_7717_peerj_3551 crossref_primary_10_1080_2162402X_2017_1338236 crossref_primary_10_1016_j_drudis_2021_01_015 crossref_primary_10_1111_fcp_12521 crossref_primary_10_1155_2019_6919463 crossref_primary_10_1124_mol_118_114447 crossref_primary_10_18632_oncotarget_3584 crossref_primary_10_3892_or_2015_4279 crossref_primary_10_1155_2018_1754085 crossref_primary_10_3389_fcell_2021_691410 crossref_primary_10_1039_C6DT03811E crossref_primary_10_1093_database_baw023 crossref_primary_10_1007_s13277_016_5209_5 crossref_primary_10_1038_srep40632 crossref_primary_10_2174_1568026623666230512123500 crossref_primary_10_3389_fphar_2020_597520 crossref_primary_10_1016_j_trecan_2017_08_007 crossref_primary_10_1016_j_neo_2024_101059 crossref_primary_10_3389_fonc_2019_01003 crossref_primary_10_1038_cdd_2015_147 crossref_primary_10_1016_j_heliyon_2023_e18798 crossref_primary_10_1038_s41598_020_73164_3 crossref_primary_10_1016_j_critrevonc_2018_08_004 crossref_primary_10_1080_01635581_2018_1412473 crossref_primary_10_1016_j_lfs_2022_121103 crossref_primary_10_3389_fimmu_2024_1417201 crossref_primary_10_1016_j_canlet_2016_01_012 crossref_primary_10_3892_ijo_2017_4206 crossref_primary_10_3390_ijms25074102 crossref_primary_10_1039_C8RA08380K crossref_primary_10_1007_s40265_017_0759_4 crossref_primary_10_18632_oncotarget_13413 crossref_primary_10_1016_j_cellsig_2023_110965 crossref_primary_10_1186_s13287_020_02018_6 crossref_primary_10_18632_oncotarget_11595 crossref_primary_10_1016_j_pep_2016_03_004 crossref_primary_10_1016_j_semcancer_2023_01_001 crossref_primary_10_2217_nnm_15_182 crossref_primary_10_1186_s13578_020_00449_5 crossref_primary_10_1016_j_mehy_2015_11_009 crossref_primary_10_1186_s12935_024_03329_x crossref_primary_10_1002_jcp_28511 crossref_primary_10_18632_oncotarget_10174 crossref_primary_10_1016_j_lfs_2023_121541 crossref_primary_10_1155_2019_8347595 crossref_primary_10_3727_096504019X15517850319579 crossref_primary_10_1038_s41746_024_01043_6 crossref_primary_10_1016_j_compbiomed_2024_108890 crossref_primary_10_1016_j_critrevonc_2020_103095 crossref_primary_10_1007_s10555_024_10177_8 crossref_primary_10_1021_acsnano_0c05589 crossref_primary_10_17795_ijcp_5897 crossref_primary_10_3892_or_2016_4848 crossref_primary_10_18632_oncotarget_10169 crossref_primary_10_1093_bib_bbae207 crossref_primary_10_1016_j_lfs_2019_05_050 crossref_primary_10_1016_j_btre_2017_11_004 crossref_primary_10_18632_oncotarget_11132 |
| Cites_doi | 10.1002/hep.22141 10.1016/j.biomaterials.2010.03.066 10.1158/0008-5472.CAN-06-3281 10.1158/0008-5472.CAN-06-2726 10.1038/sj.onc.1208511 10.1158/1078-0432.CCR-08-0584 10.1038/cr.2012.13 10.1038/nature02962 10.1016/j.cub.2006.11.033 10.1002/cncr.22774 10.1016/j.jconrel.2009.01.021 10.1038/ncb2048 10.1126/science.1227670 10.1038/199079a0 10.1186/1750-2187-5-10 10.1038/nature03128 10.1073/pnas.0703478104 10.1016/j.stem.2007.08.001 10.1038/nature09733 10.1158/0008-5472.CAN-06-2030 10.1021/bc200309h 10.1158/0008-5472.CAN-06-4238 10.1038/sj.cdd.4402283 10.1038/35102167 10.1016/j.cell.2010.01.025 10.1158/1078-0432.CCR-09-2846 10.1200/JCO.2006.08.1646 10.1038/onc.2010.566 10.1074/jbc.M111.284554 10.1158/0008-5472.CAN-05-2018 10.1016/j.addr.2011.03.005 10.1186/bcr920 10.1016/j.ccr.2008.01.013 10.1038/nature03319 10.1158/1541-7786.MCR-10-0457 10.1016/j.drup.2009.06.001 10.1016/j.cell.2005.03.032 10.1038/sj.onc.1206056 10.1158/1078-0432.CCR-09-2933 10.1158/1078-0432.CCR-07-1441 10.1158/0008-5472.CAN-10-2238 10.1016/j.drup.2011.01.003 10.1073/pnas.0702388104 10.1182/blood-2007-04-083808 10.1158/1078-0432.CCR-07-4973 10.1021/mp8002682 10.1016/j.stem.2009.04.018 10.1016/j.drup.2011.02.004 10.1152/physrev.00035.2005 10.1038/nm0797-730 10.1038/leu.2008.299 10.1158/1078-0432.CCR-0914-3 10.1038/nchembio.137 10.1002/jcb.22350 10.1016/j.ccr.2006.11.020 10.1074/jbc.M800170200 10.1016/j.jocn.2012.03.012 10.1146/annurev.med.58.062105.204854 10.1016/j.drup.2010.07.001 10.1038/sj.onc.1210356 10.1158/1535-7163.MCT-08-0573 10.1182/blood-2006-05-024687 10.1016/j.drup.2012.03.003 10.1158/0008-5472.CAN-09-1681 10.1038/nature05372 10.1016/j.drup.2009.07.001 10.4161/cc.6.19.4914 10.1158/0008-5472.CAN-07-3096 10.1073/pnas.0530291100 10.1177/107327480401100216 10.1182/blood-2009-02-206722 10.1016/j.stem.2007.08.014 10.1038/nm1483 10.1158/0008-5472.CAN-06-3557 10.1002/smll.200900621 10.1158/0008-5472.CAN-05-1343 10.1016/j.stem.2010.03.020 10.1038/nrd2781 10.1073/pnas.0915135107 10.1158/1078-0432.CCR-06-0422 10.1038/onc.2010.149 10.1016/j.nano.2010.06.010 10.1136/gut.2007.148189 10.1016/j.stem.2010.11.014 10.1073/pnas.0603672103 10.1158/0008-5472.CAN-10-2817 10.1016/j.jconrel.2008.04.024 10.1596/neo.12230 10.1038/nature09650 10.1073/pnas.0610117104 10.1016/j.jconrel.2009.09.004 10.1038/nature06835 10.1021/mp800240j 10.1016/j.drup.2010.08.001 10.1634/stemcells.2007-0166 10.1182/blood-2003-09-3064 10.1038/nature05349 10.1158/0008-5472.CAN-12-1248 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2013 Copyright Nature Publishing Group Jun 2013 Copyright © 2013 CPS and SIMM 2013 CPS and SIMM |
| Copyright_xml | – notice: The Author(s) 2013 – notice: Copyright Nature Publishing Group Jun 2013 – notice: Copyright © 2013 CPS and SIMM 2013 CPS and SIMM |
| DBID | 2RA 92L CQIGP W91 ~WA C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7QR 7T5 7TK 7TO 7U9 7X7 7XB 88E 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7N M7P P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 7QO 5PM |
| DOI | 10.1038/aps.2013.27 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Neurosciences Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Biotechnology Research Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic Biotechnology Research Abstracts |
| DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest Central Student Engineering Research Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Understanding and targeting cancer stem cells： therapeutic implications and challenges |
| EISSN | 1745-7254 |
| EndPage | 740 |
| ExternalDocumentID | PMC3674516 2987775981 23685952 10_1038_aps_2013_27 46146486 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- -05 -0E -Q- -S~ .3N 0R~ 188 1OC 23M 2RA 2WC 31~ 36B 3V. 4.4 406 53G 5GY 5VR 5VS 6J9 70F 7X7 8-1 88E 8FI 8FJ 8R4 8R5 8RM 92L 92M 9D9 9DE A8Z AADWK AANZL AATNV AAWBL AAYFA AAYJO AAZLF ABAWZ ABGIJ ABKZE ABUWG ACAOD ACBMV ACBRV ACBYP ACGFO ACGFS ACIGE ACIWK ACKTT ACPRK ACRQY ACTTH ACVWB ACXQS ACZOJ ADBBV ADFRT ADHDB ADMDM ADQMX ADRAZ ADYYL AEDAW AEFTE AEJRE AENEX AESKC AEVLU AEXYK AFBPY AFKRA AFNRJ AFRAH AFSHS AFUIB AFZJQ AGAYW AGEZK AGGBP AGHAI AHMBA AHSBF AILAN AJAOE AJCLW AJDOV AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMRJV AMYLF AOIJS AXYYD BAWUL BBNVY BENPR BFHJK BHPHI BKKNO BPHCQ BVXVI C1A CAG CAJEE CAJUS CCEZO CCPQU CHBEP CIEJG CO8 COF CQIGP CS3 CW9 DIK DNIVK DPUIP E3Z EBLON EBS EE. EIOEI EJD EMB EMOBN ESTFP F5P FA0 FDQFY FERAY FIZPM FSGXE FYUFA GX1 HCIFZ HH5 HMCUK HYE HZI HZ~ IWAJR JSO JUIAU JZLTJ K97 KQ8 LH4 LW6 M1P M48 M7P MK0 NQJWS NXXTH NYICJ O9- OK1 OVD P2P P6G PQQKQ PROAC PSQYO Q-- Q-4 Q2X R-E RNT RNTTT RPM RT5 S.. SNX SNYQT SOHCF SRMVM SV3 SWTZT T8U TAOOD TBHMF TDRGL TEORI TR2 TSG U1F U1G U5E U5O UKHRP UZ5 W91 ~88 ~NG ~WA -SE AACDK AASML AAXDM ABAKF ABZZP ACMJI AEFQL AEMSY AFBBN AGQEE AIGIU ALIPV C6C FIGPU LGEZI LOTEE NADUK ROL AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC AEZWR AFDZB AFHIU AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT SOJ ABRTQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 7QP 7QR 7T5 7TK 7TO 7U9 7XB 8FD 8FE 8FH 8FK AZQEC DWQXO FR3 GNUQQ H94 K9. LK8 M7N P64 PKEHL PQEST PQUKI PRINS 7X8 7QO 5PM |
| ID | FETCH-LOGICAL-c571t-1ba3a0010a372e0c9e5d15666bf84500de070d9214af1e9ac54c80ee7559733c3 |
| IEDL.DBID | 7X7 |
| ISSN | 1671-4083 1745-7254 |
| IngestDate | Thu Aug 21 18:26:24 EDT 2025 Tue Aug 05 11:18:52 EDT 2025 Thu Jul 10 18:27:34 EDT 2025 Fri Jul 25 08:56:37 EDT 2025 Mon Jul 21 05:57:23 EDT 2025 Thu Apr 24 23:10:56 EDT 2025 Tue Jul 01 02:04:11 EDT 2025 Fri Feb 21 02:38:48 EST 2025 Wed Feb 14 10:43:11 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | leukemia stem cell signaling pathway cancer tumor microenvironment biomarker ATP-binding cassette transporter |
| Language | English |
| License | This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c571t-1ba3a0010a372e0c9e5d15666bf84500de070d9214af1e9ac54c80ee7559733c3 |
| Notes | cancer; stem cell; leukemia; biomarker; ATP-binding cassette transporter; signaling pathway; tumor microenvironment Cancer stem cells （CSCs） have been identified as rare cell populations in many cancers, including leukemia and solid tumors. Accumulating evidence has suggested that CSCs are capable of self-renewal and differentiation into various types of cancer cells. Aberrant regulation of gene expression and some signaling pathways has been observed in CSCs compared to other tumor cells. CSCs are thought to be responsible for cancer initiation, progression, metastasis, recurrence and drug resistance. The CSC hypothesis has recently attracted much attention due to the potential for discovery and development of CSC-related therapies and the identification of key molecules involved in controlling the unique properties of CSC populations. Over the past several years, a tremendous amount of effort has been invested in the development of new drugs, such as nanomedicines, that can take advantage of the ＂Achilles＇ heel＂ of CSCs by targeting cell-surface molecular markers or various signaling pathways. Novel compounds and therapeutic strategies that selectively target CSCs have been identified, some of which have been evaluated in preclinical and clinical studies. In this article, we review new findings related to the investigation of the CSC hypothesis, and discuss the crucial pathways involved in regulating the development of CSC populations and the advances in studies of drug resistance. In addition, we review new CSC-targeted therapeutic strategies aiming to eradicate malignancies. 31-1347/R ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/aps.2013.27 |
| PMID | 23685952 |
| PQID | 1364797481 |
| PQPubID | 28815 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3674516 proquest_miscellaneous_1399910835 proquest_miscellaneous_1365508120 proquest_journals_1364797481 pubmed_primary_23685952 crossref_primary_10_1038_aps_2013_27 crossref_citationtrail_10_1038_aps_2013_27 springer_journals_10_1038_aps_2013_27 chongqing_primary_46146486 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-06-01 |
| PublicationDateYYYYMMDD | 2013-06-01 |
| PublicationDate_xml | – month: 06 year: 2013 text: 2013-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: United States – name: Shanghai |
| PublicationTitle | Acta pharmacologica Sinica |
| PublicationTitleAbbrev | Acta Pharmacol Sin |
| PublicationTitleAlternate | Acta Pharmacologica Sinica |
| PublicationYear | 2013 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Yeung, Gandhi, Wilding, Muschel, Bodmer (CR27) 2010; 107 Ritchie, Kwon, Atkins (CR74) 2011; 286 Sims-Mourtada, Izzo, Ajani, Chao (CR79) 2007; 26 Harrison, Farnie, Howell, Rock, Stylianou, Brennan (CR42) 2010; 70 Wang, Li, Ahmad, Azmi, Kong, Banerjee (CR58) 2010; 13 Feldmann, Fendrich, McGovern, Bedja, Bisht, Alvarez (CR87) 2008; 7 Simeone (CR32) 2008; 14 Fujii, You, Xu, Uematsu, Shan, He (CR85) 2007; 67 Ramaswamy, Lu, Teng, Nuovo, Li, Shapiro (CR88) 2012; 72 Roy, Srivastava, Shankar (CR36) 2010; 5 Anderson, Lutz, van Delft, Bateman, Guo, Colman (CR14) 2011; 469 Patil, Sadhukha, Ma, Panyam (CR73) 2009; 136 Konopleva, Tabe, Zeng, Andreeff (CR98) 2009; 12 Dontu, Jackson, McNicholas, Kawamura, Abdallah, Wicha (CR50) 2004; 6 Jin, Hope, Zhai, Smadja-Joffe, Dick (CR61) 2006; 12 Tang (CR11) 2012; 22 Bentires-Alj, Barbu, Fillet, Chariot, Relic, Jacobs (CR96) 2003; 22 Notta, Mullighan, Wang, Poeppl, Doulatov, Phillips (CR15) 2011; 469 Piccirillo, Reynolds, Zanetti, Lamorte, Binda, Broggi (CR9) 2006; 444 Chen, Zhang, Wei, Stueber, Taratula, Minko (CR37) 2009; 5 Gilbert, Ross (CR23) 2009; 108 Marusyk, Polyak (CR13) 2010; 1805 Reya, Clevers (CR54) 2005; 434 Prince, Sivanandan, Kaczorowski, Wolf, Kaplan, Dalerba (CR33) 2007; 104 Guo, Qiu, Wang, Chen, Rothman, Wang (CR38) 2010; 29 Feldmann, Dhara, Fendrich, Bedja, Beaty, Mullendore (CR92) 2007; 67 Merchant, Matsui (CR51) 2010; 16 Mehra, Penning, Maas, Beerepoot, van Daal, van Gils (CR68) 2006; 12 Ganta, Amiji (CR95) 2009; 6 Pradhan, Lambert, Reuther (CR46) 2007; 104 Grivennikov, Greten, Karin (CR48) 2010; 140 Jin, Lee, Ramshaw, Busfield, Peoppl, Wilkinson (CR62) 2009; 5 Vermeulen, De Sousa E Melo, van der Heijden, Cameron, de Jong, Borovski (CR83) 2010; 12 Matsui, Wang, Barber, Brennan, Smith, Borrello (CR30) 2008; 6 Cho, Wang, Nie, Chen, Shin (CR55) 2008; 14 Dalerba, Cho, Clarke (CR17) 2007; 58 Curiel (CR60) 2012; 15 Feldmann, Habbe, Dhara, Bisht, Alvarez, Fendrich (CR89) 2008; 57 Burger, Peled (CR40) 2008; 23 Campbell, Polyak (CR12) 2007; 6 Bruce, Van Der Gaag (CR2) 1963; 199 O/'Brien, Pollett, Gallinger, Dick (CR28) 2007; 445 Singh, Hawkins, Clarke, Squire, Bayani, Hide (CR19) 2004; 432 Saeki, Nomizu, Toi, Ito, Noguchi, Kobayashi (CR77) 2007; 25 Alkilany, Thompson, Boulos, Sisco, Murphy (CR65) 2012; 64 Khdair, Di, Patil, Ma, Dou, Shekhar (CR76) 2010; 141 Gundlach, Caivano, da Graca Cabreira-Hansen, Gahremanpour, Brown, Zheng (CR66) 2011; 22 Folkins, Man, Xu, Shaked, Hicklin, Kerbel (CR101) 2007; 67 Chen, Dodge, Tang, Lu, Ma, Fan (CR84) 2009; 5 LaBarge (CR56) 2010; 16 Szotek, Pieretti-Vanmarcke, Masiakos, Dinulescu, Connolly, Foster (CR8) 2006; 103 Fang, Nguyen, Leishear, Finko, Kulp, Hotz (CR10) 2005; 65 Yang, Ho, Ng, Lau, Yu, Ngai (CR21) 2008; 13 CR70 Fan, Li, Zhang, Wang, Cheng, Li (CR94) 2010; 31 Burkhardt, Hofstetter, Santillan, Shin, Foley, Ballon (CR99) 2012; 19 Guzman, Jordan (CR18) 2004; 11 Kruger, Kaplan, Luo, Zhou, Markowitz, Xiang (CR34) 2006; 108 Baud, Karin (CR39) 2009; 8 Calabrese, Poppleton, Kocak, Hogg, Fuller, Hamner (CR100) 2007; 11 Malanchi, Peinado, Kassen, Hussenet, Metzger, Chambon (CR52) 2008; 452 Ho, Ng, Lam, Hung (CR25) 2007; 67 Murphy, Stordal (CR43) 2011; 14 Bar, Chaudhry, Lin, Fan, Schreck, Matsui (CR91) 2007; 25 Ginestier, Hur, Charafe-Jauffret, Monville, Dutcher, Brown (CR20) 2007; 1 Deeley, Westlake, Cole (CR35) 2006; 86 Rountree, Senadheera, Mato, Crooks, Lu (CR22) 2008; 47 Gutierrez, Sanda, Grebliunaite, Carracedo, Salmena, Ahn (CR44) 2009; 114 He, Reguart, You, Mazieres, Xu, Lee (CR86) 2005; 24 Minderman, O'Loughlin, Pendyala, Baer (CR78) 2004; 10 Shapira, Livney, Broxterman, Assaraf (CR72) 2011; 14 Bonnet, Dick (CR3) 1997; 3 Lin, Hassan, Li, Zhao, Nooka, Sorenson (CR67) 2007; 110 Tsuruo, Iida, Tsukagoshi, Sakurai (CR75) 1981; 41 Kreso, O'Brien, van Galen, Gan, Notta, Brown (CR16) 2013; 339 Qiu, Guo, Chen, Kashiwada, Druker, Rothman (CR47) 2012; 14 McGowan, Simedrea, Ribot, Foster, Palmieri, Steeg (CR82) 2011; 9 Al-Hajj, Wicha, Benito-Hernandez, Morrison, Clarke (CR4) 2003; 100 Reya, Morrison, Clarke, Weissman (CR1) 2001; 414 Lacerda, Pusztai, Woodward (CR57) 2010; 13 Eramo, Lotti, Sette, Pilozzi, Biffoni, Di Virgilio (CR24) 2007; 15 Todaro, Alea, Di Stefano, Cammareri, Vermeulen, Iovino (CR41) 2007; 1 Kikushige, Shima, Takayanagi, Urata, Miyamoto, Iwasaki (CR63) 2010; 7 Dalerba, Dylla, Park, Liu, Wang, Cho (CR26) 2007; 104 Wang, Chiou, Chou, Chen, Huang, Peng (CR69) 2011; 7 Lee, Gao, Kim, Park, Kwon, Bae (CR102) 2008; 129 Devalapally, Duan, Seiden, Amiji (CR97) 2008; 14 O'Brien, Pollett, Gallinger, Dick (CR6) 2007; 445 Chaturvedi, Sung, Yadav, Kannappan, Aggarwal (CR49) 2011; 30 Zeng, Nusse (CR53) 2010; 6 Broxterman, Gotink, Verheul (CR71) 2009; 12 Matsui, Huff, Wang, Malehorn, Barber, Tanhehco (CR29) 2004; 103 Collins, Berry, Hyde, Stower, Maitland (CR7) 2005; 65 Chao, Alizadeh, Tang, Jan, Weissman-Tsukamoto, Zhao (CR64) 2011; 71 Clement, Sanchez, de Tribolet, Radovanovic, Ruiz i Altaba (CR93) 2007; 17 Chen, Limnander, Rothman (CR45) 2008; 111 Karhadkar, Steven Bova, Abdallah, Dhara, Gardner, Maitra (CR90) 2004; 431 Fischer, Yen, Kapoun, Wang, O'Young, Lewicki (CR80) 2011; 71 Kim, Jackson, Woolfenden, Lawrence, Babar, Vogel (CR5) 2005; 121 Li, Heidt, Dalerba, Burant, Zhang, Adsay (CR31) 2007; 67 Liu, Kopečková, Bühler, Wolf, Pan, Bauer (CR59) 2009; 6 Li, Li, Wu, Gordon, Chang, Lu (CR81) 2008; 283 CA O'Brien (BFaps201327_CR6) 2007; 445 Y Patil (BFaps201327_CR73) 2009; 136 T Reya (BFaps201327_CR54) 2005; 434 S Roy (BFaps201327_CR36) 2010; 5 A Eramo (BFaps201327_CR24) 2007; 15 CF Kim (BFaps201327_CR5) 2005; 121 P Dalerba (BFaps201327_CR17) 2007; 58 M Konopleva (BFaps201327_CR98) 2009; 12 CH Wang (BFaps201327_CR69) 2011; 7 B Ramaswamy (BFaps201327_CR88) 2012; 72 JK Burkhardt (BFaps201327_CR99) 2012; 19 A Pradhan (BFaps201327_CR46) 2007; 104 B He (BFaps201327_CR86) 2005; 24 G Dontu (BFaps201327_CR50) 2004; 6 A Shapira (BFaps201327_CR72) 2011; 14 ML Guzman (BFaps201327_CR18) 2004; 11 C Li (BFaps201327_CR31) 2007; 67 JA Burger (BFaps201327_CR40) 2008; 23 V Baud (BFaps201327_CR39) 2009; 8 J Liu (BFaps201327_CR59) 2009; 6 SS Karhadkar (BFaps201327_CR90) 2004; 431 K Anderson (BFaps201327_CR14) 2011; 469 AT Collins (BFaps201327_CR7) 2005; 65 AA Merchant (BFaps201327_CR51) 2010; 16 D Fang (BFaps201327_CR10) 2005; 65 AM Chen (BFaps201327_CR37) 2009; 5 ZF Yang (BFaps201327_CR21) 2008; 13 LL Campbell (BFaps201327_CR12) 2007; 6 N Fujii (BFaps201327_CR85) 2007; 67 RG Deeley (BFaps201327_CR35) 2006; 86 I Malanchi (BFaps201327_CR52) 2008; 452 M Bentires-Alj (BFaps201327_CR96) 2003; 22 PP Szotek (BFaps201327_CR8) 2006; 103 M Fischer (BFaps201327_CR80) 2011; 71 A Gutierrez (BFaps201327_CR44) 2009; 114 AM Alkilany (BFaps201327_CR65) 2012; 64 L Fan (BFaps201327_CR94) 2010; 31 BFaps201327_CR70 HJ Broxterman (BFaps201327_CR71) 2009; 12 PM McGowan (BFaps201327_CR82) 2011; 9 T Saeki (BFaps201327_CR77) 2007; 25 CB Rountree (BFaps201327_CR22) 2008; 47 WR Bruce (BFaps201327_CR2) 1963; 199 JA Kruger (BFaps201327_CR34) 2006; 108 H Minderman (BFaps201327_CR78) 2004; 10 DG Tang (BFaps201327_CR11) 2012; 22 G Feldmann (BFaps201327_CR89) 2008; 57 MA LaBarge (BFaps201327_CR56) 2010; 16 ES Lee (BFaps201327_CR102) 2008; 129 SK Singh (BFaps201327_CR19) 2004; 432 B Chen (BFaps201327_CR84) 2009; 5 W Matsui (BFaps201327_CR29) 2004; 103 EE Bar (BFaps201327_CR91) 2007; 25 D Bonnet (BFaps201327_CR3) 1997; 3 C Folkins (BFaps201327_CR101) 2007; 67 CA O/'Brien (BFaps201327_CR28) 2007; 445 G Feldmann (BFaps201327_CR87) 2008; 7 L Jin (BFaps201327_CR62) 2009; 5 K Li (BFaps201327_CR81) 2008; 283 CW Gundlach (BFaps201327_CR66) 2011; 22 L Vermeulen (BFaps201327_CR83) 2010; 12 V Clement (BFaps201327_CR93) 2007; 17 S Ganta (BFaps201327_CR95) 2009; 6 G Feldmann (BFaps201327_CR92) 2007; 67 H Harrison (BFaps201327_CR42) 2010; 70 A Khdair (BFaps201327_CR76) 2010; 141 CA Gilbert (BFaps201327_CR23) 2009; 108 DM Simeone (BFaps201327_CR32) 2008; 14 A Marusyk (BFaps201327_CR13) 2010; 1805 N Mehra (BFaps201327_CR68) 2006; 12 P Dalerba (BFaps201327_CR26) 2007; 104 F Notta (BFaps201327_CR15) 2011; 469 H Devalapally (BFaps201327_CR97) 2008; 14 M Al-Hajj (BFaps201327_CR4) 2003; 100 K Cho (BFaps201327_CR55) 2008; 14 T Reya (BFaps201327_CR1) 2001; 414 MP Chao (BFaps201327_CR64) 2011; 71 TM Yeung (BFaps201327_CR27) 2010; 107 YA Zeng (BFaps201327_CR53) 2010; 6 SI Grivennikov (BFaps201327_CR48) 2010; 140 J Sims-Mourtada (BFaps201327_CR79) 2007; 26 MM Ho (BFaps201327_CR25) 2007; 67 L Lacerda (BFaps201327_CR57) 2010; 13 W Matsui (BFaps201327_CR30) 2008; 6 TJ Curiel (BFaps201327_CR60) 2012; 15 ME Prince (BFaps201327_CR33) 2007; 104 EH Lin (BFaps201327_CR67) 2007; 110 A Kreso (BFaps201327_CR16) 2013; 339 Y Kikushige (BFaps201327_CR63) 2010; 7 M Murphy (BFaps201327_CR43) 2011; 14 X Qiu (BFaps201327_CR47) 2012; 14 C Ginestier (BFaps201327_CR20) 2007; 1 T Tsuruo (BFaps201327_CR75) 1981; 41 SGM Piccirillo (BFaps201327_CR9) 2006; 444 MM Chaturvedi (BFaps201327_CR49) 2011; 30 M Todaro (BFaps201327_CR41) 2007; 1 G Guo (BFaps201327_CR38) 2010; 29 TK Ritchie (BFaps201327_CR74) 2011; 286 Z Wang (BFaps201327_CR58) 2010; 13 C Calabrese (BFaps201327_CR100) 2007; 11 JL Chen (BFaps201327_CR45) 2008; 111 L Jin (BFaps201327_CR61) 2006; 12 |
| References_xml | – volume: 47 start-page: 1288 year: 2008 end-page: 97 ident: CR22 article-title: Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice publication-title: Hepatology doi: 10.1002/hep.22141 – volume: 31 start-page: 5634 year: 2010 end-page: 42 ident: CR94 article-title: Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance publication-title: Biomaterials doi: 10.1016/j.biomaterials.2010.03.066 – volume: 67 start-page: 2187 year: 2007 end-page: 96 ident: CR92 article-title: Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-3281 – volume: 67 start-page: 573 year: 2007 end-page: 9 ident: CR85 article-title: An antagonist of dishevelled protein-protein interaction suppresses β-catenin-dependent tumor cell frowth publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-2726 – volume: 24 start-page: 3054 year: 2005 end-page: 8 ident: CR86 article-title: Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations publication-title: Oncogene doi: 10.1038/sj.onc.1208511 – volume: 14 start-page: 5646 year: 2008 end-page: 8 ident: CR32 article-title: Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0584 – volume: 22 start-page: 457 year: 2012 end-page: 72 ident: CR11 article-title: Understanding cancer stem cell heterogeneity and plasticity publication-title: Cell Res doi: 10.1038/cr.2012.13 – volume: 431 start-page: 707 year: 2004 end-page: 12 ident: CR90 article-title: Hedgehog signalling in prostate regeneration, neoplasia and metastasis publication-title: Nature doi: 10.1038/nature02962 – volume: 17 start-page: 165 year: 2007 end-page: 72 ident: CR93 article-title: HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity publication-title: Curr Biol doi: 10.1016/j.cub.2006.11.033 – volume: 110 start-page: 534 year: 2007 end-page: 42 ident: CR67 article-title: Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence publication-title: Cancer doi: 10.1002/cncr.22774 – volume: 136 start-page: 21 year: 2009 end-page: 9 ident: CR73 article-title: Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance publication-title: J Control Release doi: 10.1016/j.jconrel.2009.01.021 – volume: 12 start-page: 468 year: 2010 end-page: 76 ident: CR83 article-title: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment publication-title: Nat Cell Biol doi: 10.1038/ncb2048 – volume: 339 start-page: 543 year: 2013 end-page: 8 ident: CR16 article-title: Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer publication-title: Science doi: 10.1126/science.1227670 – volume: 199 start-page: 79 year: 1963 end-page: 80 ident: CR2 article-title: A quantitative assay for the number of murine lymphoma cells capable of proliferation publication-title: Nature doi: 10.1038/199079a0 – volume: 5 start-page: 10 year: 2010 ident: CR36 article-title: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer publication-title: J Mol Signal doi: 10.1186/1750-2187-5-10 – volume: 432 start-page: 396 year: 2004 end-page: 401 ident: CR19 article-title: Identification of human brain tumour initiating cells publication-title: Nature doi: 10.1038/nature03128 – volume: 104 start-page: 10158 year: 2007 end-page: 63 ident: CR26 article-title: Phenotypic characterization of human colorectal cancer stem cells publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0703478104 – volume: 1 start-page: 389 year: 2007 end-page: 402 ident: CR41 article-title: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2007.08.001 – volume: 469 start-page: 362 year: 2011 end-page: 7 ident: CR15 article-title: Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells publication-title: Nature doi: 10.1038/nature09733 – volume: 67 start-page: 1030 year: 2007 end-page: 7 ident: CR31 article-title: Identification of pancreatic cancer stem cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-2030 – volume: 22 start-page: 1706 year: 2011 end-page: 14 ident: CR66 article-title: Synthesis and evaluation of an anti-MLC1×anti-CD90 bispecific antibody for targeting and retaining bone-marrow-derived multipotent stromal cells in infarcted myocardium publication-title: Bioconjug Chem doi: 10.1021/bc200309h – volume: 67 start-page: 3560 year: 2007 end-page: 4 ident: CR101 article-title: Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem — like cell fraction in glioma xenograft tumors publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-4238 – volume: 15 start-page: 504 year: 2007 end-page: 14 ident: CR24 article-title: Identification and expansion of the tumorigenic lung cancer stem cell population publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4402283 – volume: 414 start-page: 105 year: 2001 end-page: 11 ident: CR1 article-title: Stem cells, cancer, and cancer stem cells publication-title: Nature doi: 10.1038/35102167 – volume: 140 start-page: 883 year: 2010 end-page: 99 ident: CR48 article-title: Immunity, inflammation, and cancer publication-title: Cell doi: 10.1016/j.cell.2010.01.025 – volume: 16 start-page: 3130 year: 2010 end-page: 40 ident: CR51 article-title: Targeting Hedgehog — a cancer stem cell pathway publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-2846 – volume: 25 start-page: 411 year: 2007 end-page: 7 ident: CR77 article-title: Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2006.08.1646 – volume: 30 start-page: 1615 year: 2011 end-page: 30 ident: CR49 article-title: NF-[kappa]B addiction and its role in cancer: one size does not fit all publication-title: Oncogene doi: 10.1038/onc.2010.566 – volume: 286 start-page: 39489 year: 2011 end-page: 96 ident: CR74 article-title: Conformational analysis of Human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and Inhibition by the antibodies MRK16 and UIC2 publication-title: J Biol Chem doi: 10.1074/jbc.M111.284554 – volume: 65 start-page: 10946 year: 2005 end-page: 51 ident: CR7 article-title: Prospective identification of tumorigenic prostate cancer stem cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-2018 – volume: 64 start-page: 190 year: 2012 end-page: 9 ident: CR65 article-title: Gold nanorods: Their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2011.03.005 – volume: 6 start-page: R605 year: 2004 end-page: R615 ident: CR50 article-title: Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells publication-title: Breast Cancer Res doi: 10.1186/bcr920 – volume: 13 start-page: 153 year: 2008 end-page: 66 ident: CR21 article-title: Significance of CD90 cancer stem cells in human liver cancer publication-title: Cancer Cell doi: 10.1016/j.ccr.2008.01.013 – volume: 434 start-page: 843 year: 2005 end-page: 50 ident: CR54 article-title: Wnt signalling in stem cells and cancer publication-title: Nature doi: 10.1038/nature03319 – volume: 9 start-page: 834 year: 2011 end-page: 44 ident: CR82 article-title: Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-10-0457 – volume: 12 start-page: 103 year: 2009 end-page: 13 ident: CR98 article-title: Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches publication-title: Drug Resist Updat doi: 10.1016/j.drup.2009.06.001 – volume: 121 start-page: 823 year: 2005 end-page: 35 ident: CR5 article-title: Identification of bronchioalveolar stem cells in normal lung and lung cancer publication-title: Cell doi: 10.1016/j.cell.2005.03.032 – volume: 22 start-page: 90 year: 2003 end-page: 7 ident: CR96 article-title: NF-[kappa]B transcription factor induces drug resistance through MDR1 expression in cancer cells publication-title: Oncogene doi: 10.1038/sj.onc.1206056 – volume: 16 start-page: 3121 year: 2010 end-page: 9 ident: CR56 article-title: The difficulty of targeting cancer stem cell niches publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-2933 – volume: 14 start-page: 1310 year: 2008 end-page: 6 ident: CR55 article-title: Therapeutic nanoparticles for drug Delivery in cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-1441 – volume: 71 start-page: 1374 year: 2011 end-page: 84 ident: CR64 article-title: Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-2238 – volume: 14 start-page: 150 year: 2011 end-page: 63 ident: CR72 article-title: Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance publication-title: Drug Resist Updat doi: 10.1016/j.drup.2011.01.003 – volume: 104 start-page: 18502 year: 2007 end-page: 7 ident: CR46 article-title: Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0702388104 – volume: 111 start-page: 1677 year: 2008 end-page: 85 ident: CR45 article-title: Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene publication-title: Blood doi: 10.1182/blood-2007-04-083808 – volume: 14 start-page: 3193 year: 2008 end-page: 203 ident: CR97 article-title: Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric Nanoparticles publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-4973 – volume: 6 start-page: 959 year: 2009 end-page: 70 ident: CR59 article-title: Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells publication-title: Mol Pharm doi: 10.1021/mp8002682 – volume: 5 start-page: 31 year: 2009 end-page: 42 ident: CR62 article-title: Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells publication-title: Cell Stem Cell doi: 10.1016/j.stem.2009.04.018 – volume: 14 start-page: 177 year: 2011 end-page: 90 ident: CR43 article-title: Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review publication-title: Drug Resistance Updates doi: 10.1016/j.drup.2011.02.004 – volume: 86 start-page: 849 year: 2006 end-page: 99 ident: CR35 article-title: Transmembrane transport of Endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins publication-title: Physiol Rev doi: 10.1152/physrev.00035.2005 – volume: 3 start-page: 730 year: 1997 end-page: 7 ident: CR3 article-title: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell publication-title: Nat Med doi: 10.1038/nm0797-730 – ident: CR70 – volume: 23 start-page: 43 year: 2008 end-page: 52 ident: CR40 article-title: CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers publication-title: Leukemia doi: 10.1038/leu.2008.299 – volume: 10 start-page: 1826 year: 2004 end-page: 34 ident: CR78 article-title: VX-710 (Biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-0914-3 – volume: 5 start-page: 100 year: 2009 end-page: 7 ident: CR84 article-title: Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer publication-title: Nat Chem Biol doi: 10.1038/nchembio.137 – volume: 108 start-page: 1031 year: 2009 end-page: 8 ident: CR23 article-title: Cancer stem cells: cell culture, markers, and targets for new therapies publication-title: J Cell Biochem doi: 10.1002/jcb.22350 – volume: 11 start-page: 69 year: 2007 end-page: 82 ident: CR100 article-title: A perivascular niche for brain tumor stem cells publication-title: Cancer Cell doi: 10.1016/j.ccr.2006.11.020 – volume: 283 start-page: 8046 year: 2008 end-page: 54 ident: CR81 article-title: Modulation of notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3 publication-title: J Biol Chem doi: 10.1074/jbc.M800170200 – volume: 19 start-page: 1568 year: 2012 end-page: 72 ident: CR99 article-title: Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench publication-title: J Clin Neurosci doi: 10.1016/j.jocn.2012.03.012 – volume: 58 start-page: 267 year: 2007 end-page: 84 ident: CR17 article-title: Cancer stem cells: models and concepts publication-title: Annu Rev Med doi: 10.1146/annurev.med.58.062105.204854 – volume: 13 start-page: 109 year: 2010 end-page: 18 ident: CR58 article-title: Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance publication-title: Drug Resist Updat doi: 10.1016/j.drup.2010.07.001 – volume: 26 start-page: 5674 year: 2007 end-page: 9 ident: CR79 article-title: Sonic hedgehog promotes multiple drug resistance by regulation of drug transport publication-title: Oncogene doi: 10.1038/sj.onc.1210356 – volume: 7 start-page: 2725 year: 2008 end-page: 35 ident: CR87 article-title: An orally bioavailable small-molecule inhibitor of hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-08-0573 – volume: 108 start-page: 3906 year: 2006 end-page: 12 ident: CR34 article-title: Characterization of stem cell-like cancer cells in immune-competent mice publication-title: Blood doi: 10.1182/blood-2006-05-024687 – volume: 15 start-page: 106 year: 2012 end-page: 13 ident: CR60 article-title: Immunotherapy: a useful strategy to help combat multidrug resistance publication-title: Drug Resistance Updates doi: 10.1016/j.drup.2012.03.003 – volume: 70 start-page: 709 year: 2010 end-page: 18 ident: CR42 article-title: Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-1681 – volume: 445 start-page: 106 year: 2007 end-page: 10 ident: CR28 article-title: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice publication-title: Nature doi: 10.1038/nature05372 – volume: 12 start-page: 114 year: 2009 end-page: 26 ident: CR71 article-title: Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib publication-title: Drug Resist Updat doi: 10.1016/j.drup.2009.07.001 – volume: 6 start-page: 2332 year: 2007 end-page: 8 ident: CR12 article-title: Breast tumor heterogeneity: cancer stem cells or clonal evolution? publication-title: Cell Cycle doi: 10.4161/cc.6.19.4914 – volume: 6 start-page: 190 year: 2008 end-page: 7 ident: CR30 article-title: Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-3096 – volume: 41 start-page: 1967 year: 1981 end-page: 72 ident: CR75 article-title: Overcoming of vincristine resistance in P388 leukemia and through enhanced cytotoxicity of vincristine and vinblastine by verapamil publication-title: Cancer Res – volume: 100 start-page: 3983 year: 2003 end-page: 8 ident: CR4 article-title: Prospective identification of tumorigenic breast cancer cells publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0530291100 – volume: 1805 start-page: 105 year: 2010 end-page: 17 ident: CR13 article-title: Tumor heterogeneity: causes and consequences publication-title: Biochim Biophys Acta – volume: 11 start-page: 97 year: 2004 end-page: 104 ident: CR18 article-title: Considerations for targeting malignant stem cells in leukemia publication-title: Cancer Control doi: 10.1177/107327480401100216 – volume: 114 start-page: 647 year: 2009 end-page: 50 ident: CR44 article-title: High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia publication-title: Blood doi: 10.1182/blood-2009-02-206722 – volume: 1 start-page: 555 year: 2007 end-page: 67 ident: CR20 article-title: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome publication-title: Cell Stem Cell doi: 10.1016/j.stem.2007.08.014 – volume: 12 start-page: 1167 year: 2006 end-page: 74 ident: CR61 article-title: Targeting of CD44 eradicates human acute myeloid leukemic stem cells publication-title: Nat Med doi: 10.1038/nm1483 – volume: 67 start-page: 4827 year: 2007 end-page: 33 ident: CR25 article-title: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-3557 – volume: 5 start-page: 2673 year: 2009 end-page: 7 ident: CR37 article-title: Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells publication-title: Small doi: 10.1002/smll.200900621 – volume: 65 start-page: 9328 year: 2005 end-page: 37 ident: CR10 article-title: A tumorigenic subpopulation with stem cell properties in melanomas publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-1343 – volume: 6 start-page: 568 year: 2010 end-page: 77 ident: CR53 article-title: Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture publication-title: Cell Stem Cell doi: 10.1016/j.stem.2010.03.020 – volume: 8 start-page: 33 year: 2009 end-page: 40 ident: CR39 article-title: Is NF-[kappa]B a good target for cancer therapy? Hopes and pitfalls publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2781 – volume: 445 start-page: 106 year: 2007 end-page: 10 ident: CR6 article-title: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice publication-title: Nature doi: 10.1038/nature05372 – volume: 107 start-page: 3722 year: 2010 end-page: 7 ident: CR27 article-title: Cancer stem cells from colorectal cancer-derived cell lines publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0915135107 – volume: 12 start-page: 4859 year: 2006 end-page: 66 ident: CR68 article-title: Progenitor marker CD133 mRNA Is elevated in peripheral blood of cancer patients with bone metastases publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-0422 – volume: 29 start-page: 3845 year: 2010 end-page: 53 ident: CR38 article-title: Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells publication-title: Oncogene doi: 10.1038/onc.2010.149 – volume: 7 start-page: 69 year: 2011 end-page: 79 ident: CR69 article-title: Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody publication-title: Nanomedicine doi: 10.1016/j.nano.2010.06.010 – volume: 57 start-page: 1420 year: 2008 end-page: 30 ident: CR89 article-title: Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer publication-title: Gut doi: 10.1136/gut.2007.148189 – volume: 7 start-page: 708 year: 2010 end-page: 17 ident: CR63 article-title: TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells publication-title: Cell Stem Cell doi: 10.1016/j.stem.2010.11.014 – volume: 103 start-page: 11154 year: 2006 end-page: 9 ident: CR8 article-title: Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0603672103 – volume: 71 start-page: 1520 year: 2011 end-page: 5 ident: CR80 article-title: Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-2817 – volume: 129 start-page: 228 year: 2008 end-page: 36 ident: CR102 article-title: Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance publication-title: J Control Release doi: 10.1016/j.jconrel.2008.04.024 – volume: 14 start-page: 547 year: 2012 end-page: 58 ident: CR47 article-title: A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis publication-title: Neoplasia doi: 10.1596/neo.12230 – volume: 469 start-page: 356 year: 2011 end-page: 61 ident: CR14 article-title: Genetic variegation of clonal architecture and propagating cells in leukaemia publication-title: Nature doi: 10.1038/nature09650 – volume: 104 start-page: 973 year: 2007 end-page: 8 ident: CR33 article-title: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0610117104 – volume: 141 start-page: 137 year: 2010 end-page: 44 ident: CR76 article-title: Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance publication-title: J Control Release doi: 10.1016/j.jconrel.2009.09.004 – volume: 452 start-page: 650 year: 2008 end-page: 3 ident: CR52 article-title: Cutaneous cancer stem cell maintenance is dependent on [bgr]-catenin signalling publication-title: Nature doi: 10.1038/nature06835 – volume: 6 start-page: 928 year: 2009 end-page: 39 ident: CR95 article-title: Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells publication-title: Mol Pharm doi: 10.1021/mp800240j – volume: 13 start-page: 99 year: 2010 end-page: 108 ident: CR57 article-title: The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches publication-title: Drug Resist Updat doi: 10.1016/j.drup.2010.08.001 – volume: 25 start-page: 2524 year: 2007 end-page: 33 ident: CR91 article-title: Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma publication-title: Stem Cells doi: 10.1634/stemcells.2007-0166 – volume: 103 start-page: 2332 year: 2004 end-page: 6 ident: CR29 article-title: Characterization of clonogenic multiple myeloma cells publication-title: Blood doi: 10.1182/blood-2003-09-3064 – volume: 444 start-page: 761 year: 2006 end-page: 5 ident: CR9 article-title: Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells publication-title: Nature doi: 10.1038/nature05349 – volume: 72 start-page: 5048 year: 2012 end-page: 59 ident: CR88 article-title: Hedgehog signaling Is a novel therapeutic target in tamoxifen-resistant breast cancer abarrantly activated by PI3K/AKT pathway publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-12-1248 – volume: 64 start-page: 190 year: 2012 ident: BFaps201327_CR65 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2011.03.005 – volume: 86 start-page: 849 year: 2006 ident: BFaps201327_CR35 publication-title: Physiol Rev doi: 10.1152/physrev.00035.2005 – volume: 339 start-page: 543 year: 2013 ident: BFaps201327_CR16 publication-title: Science doi: 10.1126/science.1227670 – volume: 14 start-page: 1310 year: 2008 ident: BFaps201327_CR55 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-1441 – volume: 13 start-page: 153 year: 2008 ident: BFaps201327_CR21 publication-title: Cancer Cell doi: 10.1016/j.ccr.2008.01.013 – volume: 71 start-page: 1520 year: 2011 ident: BFaps201327_CR80 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-2817 – volume: 26 start-page: 5674 year: 2007 ident: BFaps201327_CR79 publication-title: Oncogene doi: 10.1038/sj.onc.1210356 – volume: 14 start-page: 177 year: 2011 ident: BFaps201327_CR43 publication-title: Drug Resistance Updates doi: 10.1016/j.drup.2011.02.004 – volume: 67 start-page: 4827 year: 2007 ident: BFaps201327_CR25 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-3557 – volume: 67 start-page: 3560 year: 2007 ident: BFaps201327_CR101 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-4238 – volume: 445 start-page: 106 year: 2007 ident: BFaps201327_CR6 publication-title: Nature doi: 10.1038/nature05372 – volume: 5 start-page: 10 year: 2010 ident: BFaps201327_CR36 publication-title: J Mol Signal doi: 10.1186/1750-2187-5-10 – volume: 41 start-page: 1967 year: 1981 ident: BFaps201327_CR75 publication-title: Cancer Res – volume: 111 start-page: 1677 year: 2008 ident: BFaps201327_CR45 publication-title: Blood doi: 10.1182/blood-2007-04-083808 – volume: 7 start-page: 69 year: 2011 ident: BFaps201327_CR69 publication-title: Nanomedicine doi: 10.1016/j.nano.2010.06.010 – volume: 29 start-page: 3845 year: 2010 ident: BFaps201327_CR38 publication-title: Oncogene doi: 10.1038/onc.2010.149 – volume: 15 start-page: 504 year: 2007 ident: BFaps201327_CR24 publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4402283 – volume: 1 start-page: 389 year: 2007 ident: BFaps201327_CR41 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2007.08.001 – volume: 432 start-page: 396 year: 2004 ident: BFaps201327_CR19 publication-title: Nature doi: 10.1038/nature03128 – volume: 14 start-page: 150 year: 2011 ident: BFaps201327_CR72 publication-title: Drug Resist Updat doi: 10.1016/j.drup.2011.01.003 – volume: 5 start-page: 100 year: 2009 ident: BFaps201327_CR84 publication-title: Nat Chem Biol doi: 10.1038/nchembio.137 – volume: 141 start-page: 137 year: 2010 ident: BFaps201327_CR76 publication-title: J Control Release doi: 10.1016/j.jconrel.2009.09.004 – volume: 121 start-page: 823 year: 2005 ident: BFaps201327_CR5 publication-title: Cell doi: 10.1016/j.cell.2005.03.032 – volume: 414 start-page: 105 year: 2001 ident: BFaps201327_CR1 publication-title: Nature doi: 10.1038/35102167 – volume: 3 start-page: 730 year: 1997 ident: BFaps201327_CR3 publication-title: Nat Med doi: 10.1038/nm0797-730 – volume: 72 start-page: 5048 year: 2012 ident: BFaps201327_CR88 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-12-1248 – volume: 444 start-page: 761 year: 2006 ident: BFaps201327_CR9 publication-title: Nature doi: 10.1038/nature05349 – volume: 10 start-page: 1826 year: 2004 ident: BFaps201327_CR78 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-0914-3 – volume: 12 start-page: 114 year: 2009 ident: BFaps201327_CR71 publication-title: Drug Resist Updat doi: 10.1016/j.drup.2009.07.001 – volume: 71 start-page: 1374 year: 2011 ident: BFaps201327_CR64 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-2238 – volume: 17 start-page: 165 year: 2007 ident: BFaps201327_CR93 publication-title: Curr Biol doi: 10.1016/j.cub.2006.11.033 – volume: 129 start-page: 228 year: 2008 ident: BFaps201327_CR102 publication-title: J Control Release doi: 10.1016/j.jconrel.2008.04.024 – volume: 11 start-page: 97 year: 2004 ident: BFaps201327_CR18 publication-title: Cancer Control doi: 10.1177/107327480401100216 – volume: 22 start-page: 90 year: 2003 ident: BFaps201327_CR96 publication-title: Oncogene doi: 10.1038/sj.onc.1206056 – volume: 6 start-page: 928 year: 2009 ident: BFaps201327_CR95 publication-title: Mol Pharm doi: 10.1021/mp800240j – volume: 12 start-page: 103 year: 2009 ident: BFaps201327_CR98 publication-title: Drug Resist Updat doi: 10.1016/j.drup.2009.06.001 – volume: 16 start-page: 3130 year: 2010 ident: BFaps201327_CR51 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-2846 – volume: 6 start-page: 2332 year: 2007 ident: BFaps201327_CR12 publication-title: Cell Cycle doi: 10.4161/cc.6.19.4914 – volume: 445 start-page: 106 year: 2007 ident: BFaps201327_CR28 publication-title: Nature doi: 10.1038/nature05372 – volume: 6 start-page: 959 year: 2009 ident: BFaps201327_CR59 publication-title: Mol Pharm doi: 10.1021/mp8002682 – volume: 6 start-page: 190 year: 2008 ident: BFaps201327_CR30 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-3096 – volume: 104 start-page: 18502 year: 2007 ident: BFaps201327_CR46 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0702388104 – volume: 25 start-page: 411 year: 2007 ident: BFaps201327_CR77 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.08.1646 – volume: 65 start-page: 9328 year: 2005 ident: BFaps201327_CR10 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-1343 – volume: 12 start-page: 468 year: 2010 ident: BFaps201327_CR83 publication-title: Nat Cell Biol doi: 10.1038/ncb2048 – volume: 108 start-page: 1031 year: 2009 ident: BFaps201327_CR23 publication-title: J Cell Biochem doi: 10.1002/jcb.22350 – volume: 104 start-page: 10158 year: 2007 ident: BFaps201327_CR26 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0703478104 – volume: 114 start-page: 647 year: 2009 ident: BFaps201327_CR44 publication-title: Blood doi: 10.1182/blood-2009-02-206722 – volume: 65 start-page: 10946 year: 2005 ident: BFaps201327_CR7 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-2018 – volume: 14 start-page: 5646 year: 2008 ident: BFaps201327_CR32 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0584 – volume: 67 start-page: 2187 year: 2007 ident: BFaps201327_CR92 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-3281 – volume: 47 start-page: 1288 year: 2008 ident: BFaps201327_CR22 publication-title: Hepatology doi: 10.1002/hep.22141 – volume: 13 start-page: 99 year: 2010 ident: BFaps201327_CR57 publication-title: Drug Resist Updat doi: 10.1016/j.drup.2010.08.001 – volume: 16 start-page: 3121 year: 2010 ident: BFaps201327_CR56 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-2933 – volume: 5 start-page: 31 year: 2009 ident: BFaps201327_CR62 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2009.04.018 – volume: 110 start-page: 534 year: 2007 ident: BFaps201327_CR67 publication-title: Cancer doi: 10.1002/cncr.22774 – volume: 67 start-page: 573 year: 2007 ident: BFaps201327_CR85 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-2726 – volume: 25 start-page: 2524 year: 2007 ident: BFaps201327_CR91 publication-title: Stem Cells doi: 10.1634/stemcells.2007-0166 – volume: 136 start-page: 21 year: 2009 ident: BFaps201327_CR73 publication-title: J Control Release doi: 10.1016/j.jconrel.2009.01.021 – volume: 5 start-page: 2673 year: 2009 ident: BFaps201327_CR37 publication-title: Small doi: 10.1002/smll.200900621 – volume: 283 start-page: 8046 year: 2008 ident: BFaps201327_CR81 publication-title: J Biol Chem doi: 10.1074/jbc.M800170200 – volume: 31 start-page: 5634 year: 2010 ident: BFaps201327_CR94 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2010.03.066 – volume: 469 start-page: 362 year: 2011 ident: BFaps201327_CR15 publication-title: Nature doi: 10.1038/nature09733 – volume: 1805 start-page: 105 year: 2010 ident: BFaps201327_CR13 publication-title: Biochim Biophys Acta – volume: 6 start-page: R605 year: 2004 ident: BFaps201327_CR50 publication-title: Breast Cancer Res doi: 10.1186/bcr920 – volume: 100 start-page: 3983 year: 2003 ident: BFaps201327_CR4 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0530291100 – volume: 7 start-page: 708 year: 2010 ident: BFaps201327_CR63 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2010.11.014 – volume: 11 start-page: 69 year: 2007 ident: BFaps201327_CR100 publication-title: Cancer Cell doi: 10.1016/j.ccr.2006.11.020 – volume: 22 start-page: 1706 year: 2011 ident: BFaps201327_CR66 publication-title: Bioconjug Chem doi: 10.1021/bc200309h – volume: 103 start-page: 11154 year: 2006 ident: BFaps201327_CR8 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0603672103 – volume: 24 start-page: 3054 year: 2005 ident: BFaps201327_CR86 publication-title: Oncogene doi: 10.1038/sj.onc.1208511 – volume: 12 start-page: 1167 year: 2006 ident: BFaps201327_CR61 publication-title: Nat Med doi: 10.1038/nm1483 – volume: 67 start-page: 1030 year: 2007 ident: BFaps201327_CR31 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-2030 – volume: 108 start-page: 3906 year: 2006 ident: BFaps201327_CR34 publication-title: Blood doi: 10.1182/blood-2006-05-024687 – volume: 8 start-page: 33 year: 2009 ident: BFaps201327_CR39 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2781 – ident: BFaps201327_CR70 – volume: 12 start-page: 4859 year: 2006 ident: BFaps201327_CR68 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-0422 – volume: 286 start-page: 39489 year: 2011 ident: BFaps201327_CR74 publication-title: J Biol Chem doi: 10.1074/jbc.M111.284554 – volume: 434 start-page: 843 year: 2005 ident: BFaps201327_CR54 publication-title: Nature doi: 10.1038/nature03319 – volume: 19 start-page: 1568 year: 2012 ident: BFaps201327_CR99 publication-title: J Clin Neurosci doi: 10.1016/j.jocn.2012.03.012 – volume: 15 start-page: 106 year: 2012 ident: BFaps201327_CR60 publication-title: Drug Resistance Updates doi: 10.1016/j.drup.2012.03.003 – volume: 9 start-page: 834 year: 2011 ident: BFaps201327_CR82 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-10-0457 – volume: 140 start-page: 883 year: 2010 ident: BFaps201327_CR48 publication-title: Cell doi: 10.1016/j.cell.2010.01.025 – volume: 13 start-page: 109 year: 2010 ident: BFaps201327_CR58 publication-title: Drug Resist Updat doi: 10.1016/j.drup.2010.07.001 – volume: 57 start-page: 1420 year: 2008 ident: BFaps201327_CR89 publication-title: Gut doi: 10.1136/gut.2007.148189 – volume: 199 start-page: 79 year: 1963 ident: BFaps201327_CR2 publication-title: Nature doi: 10.1038/199079a0 – volume: 58 start-page: 267 year: 2007 ident: BFaps201327_CR17 publication-title: Annu Rev Med doi: 10.1146/annurev.med.58.062105.204854 – volume: 452 start-page: 650 year: 2008 ident: BFaps201327_CR52 publication-title: Nature doi: 10.1038/nature06835 – volume: 107 start-page: 3722 year: 2010 ident: BFaps201327_CR27 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0915135107 – volume: 6 start-page: 568 year: 2010 ident: BFaps201327_CR53 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2010.03.020 – volume: 104 start-page: 973 year: 2007 ident: BFaps201327_CR33 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0610117104 – volume: 14 start-page: 547 year: 2012 ident: BFaps201327_CR47 publication-title: Neoplasia doi: 10.1596/neo.12230 – volume: 7 start-page: 2725 year: 2008 ident: BFaps201327_CR87 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-08-0573 – volume: 22 start-page: 457 year: 2012 ident: BFaps201327_CR11 publication-title: Cell Res doi: 10.1038/cr.2012.13 – volume: 469 start-page: 356 year: 2011 ident: BFaps201327_CR14 publication-title: Nature doi: 10.1038/nature09650 – volume: 103 start-page: 2332 year: 2004 ident: BFaps201327_CR29 publication-title: Blood doi: 10.1182/blood-2003-09-3064 – volume: 431 start-page: 707 year: 2004 ident: BFaps201327_CR90 publication-title: Nature doi: 10.1038/nature02962 – volume: 30 start-page: 1615 year: 2011 ident: BFaps201327_CR49 publication-title: Oncogene doi: 10.1038/onc.2010.566 – volume: 70 start-page: 709 year: 2010 ident: BFaps201327_CR42 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-1681 – volume: 1 start-page: 555 year: 2007 ident: BFaps201327_CR20 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2007.08.014 – volume: 23 start-page: 43 year: 2008 ident: BFaps201327_CR40 publication-title: Leukemia doi: 10.1038/leu.2008.299 – volume: 14 start-page: 3193 year: 2008 ident: BFaps201327_CR97 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-4973 |
| SSID | ssj0032319 |
| Score | 2.5451128 |
| SecondaryResourceType | review_article |
| Snippet | Cancer stem cells （CSCs） have been identified as rare cell populations in many cancers, including leukemia and solid tumors. Accumulating evidence has... Cancer stem cells (CSCs) have been identified as rare cell populations in many cancers, including leukemia and solid tumors. Accumulating evidence has... |
| SourceID | pubmedcentral proquest pubmed crossref springer chongqing |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 732 |
| SubjectTerms | Animals Antineoplastic Agents - pharmacology Biomedical and Life Sciences Biomedicine Cell Differentiation - physiology CSC Disease Progression Drug Design Drug Resistance, Neoplasm Humans Immunology Internal Medicine Medical Microbiology Molecular Targeted Therapy Neoplasm Metastasis Neoplasm Recurrence, Local Neoplasms - drug therapy Neoplasms - pathology Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - metabolism Pharmacology/Toxicology Review Vaccine 信号通路 分子识别 干细胞治疗 细胞群体 肿瘤干细胞 肿瘤细胞 自我更新 |
| SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swED917GUv08YYC2PIk4AHRJgdO7GDhBBCVGgSiAeKeLMc16GVqhTaIq3__Xz5oqWIpyjyXeSPc_w72_c7gF1DVeaEzcPc4G5VKtLQg1gXUmNSSnNn-zlu6F9dJ5c98fc-vu9Ak4yz7sDpm64d5pPqTUZH_57mp37Cn1Qh4-qPeUTebcaPIvkBPvolSeIMvRLtcQL3IAZxMEskOkyK14F6r5SRXmEwLh6e_KKxvEytYM_VK5SvzlHL5an7BT7XuJKcVYbwFTquWIf9m4qYen5Ibl_irKaHZJ_cvFBWz7_BXW8xxoX4B6muiOObRcOYEGR8JrjPPz0mC1FbZLhwJ73UtE1-lukG9LoXt-eXYZ1xIbSxZLOQZYYbdBMNl5GjNnVxHx28JMuViCntO_-H6KcREyZnLjU2FlZR5yT6JZxb_h3WinHhfgARzHpFYaVXELkVmZRO8tgqZWOacxvAVtvZ-rFi1tDCg4VEqCSAg6b3ta25yjFlxkiXZ-ZcaT9sGodNRzKA3Va4-dCbYtvNMOrGzDRD-nzvUikWwO-22M8w7E5TuPFzKePdOA-E6HsyCLQRzgawWVlGW5cIOf7TOApALtlMK4AM38slxXBQMn3zRGIi5QD2GutaqPpqE7feb-JP-BRVyTxCyrZhbTZ5dr88pJplO-V0-Q8p_yEv priority: 102 providerName: Scholars Portal – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NS-UwEB9cvexl8XvrFxHUg1g3adIm9SYPRQTFg0-8hTQvXQXpU_s8-N-b6Zd9-2TxVEpmSppMkt8kk98A7BmqMidsHuYGd6tSkYYexLqQGpNSmjs7ynFD_-o6uRiKy_v4vuHZLpuwyprSspqm2-iwP-YZubUZP47kD1hAznY050EyaKdd7oEKYl2WSHSKFG8u41Gu-spIofAwLv6--IVheimawZezYZL_nJVWS9D5IvxqsCM5rWu7BHOuWIaDm5p8-v2I3H7epSqPyAG5-aSlfl-Bu2H_HgvxD1KHgeObxc5_JcjqTHAvvzwhvZtZ5LEXd15p2jYHS7kKw_Oz28FF2GRVCG0s2SRkmeEGXUHDZeSoTV08QicuyXIlYkpHzs8CozRiwuTMpcbGwirqnETfg3PL12C-GBfuNxDBrFcUVnoFkVuRSekkj61SNqY5twFsdI2tn2v2DC08IEiESgI4bFtf24aPHNNiPOnqXJwr7btNY7fpSAaw1wm3H_pSbKvtRt2MxVIzpMj3bpNiAex2xX4UYXOawo3fKhnvqnmwQ_8ng2AaIWsA67VldHWJkMc_jaMA5JTNdALI4j1dUjw-VGzePJGYLDmA_da6elWf_cWNb8ptws-oztwRUrYF85PXN7ft8dMk26nGzQcuWxqL priority: 102 providerName: Springer Nature |
| Title | Understanding and targeting cancer stem cells： therapeutic implications and challenges |
| URI | http://lib.cqvip.com/qk/95561A/201306/46146486.html https://link.springer.com/article/10.1038/aps.2013.27 https://www.ncbi.nlm.nih.gov/pubmed/23685952 https://www.proquest.com/docview/1364797481 https://www.proquest.com/docview/1365508120 https://www.proquest.com/docview/1399910835 https://pubmed.ncbi.nlm.nih.gov/PMC3674516 |
| Volume | 34 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swED-29mF7Kfue265o0PVh1KtkyZa8l9GEhjJoCKMZeROyLG-F4aR1-tD_fjp_JVlGX2xsn4wtnaTfnU6_Azg2VGVO2CIsDHqrUpGGHsS6kBqTUlo4mxfo0L8aJ5dT8X0Wz1qHW9WGVXZjYj1Q53OLPvIzhkTnHvwq9m1xG2LWKFxdbVNoPIVdpC7DkC456w0u7rELwl-WSLSTFG_351GuzswCuboZ_4LpZJ75kab8devnis3ZaQtybkdO_rN8Ws9Koxew18JJct60_0t44spXcDJp-KgfTsn1antVdUpOyGTFVP3wGn5O17e2EH8iTWQ4XlnUhzuCRM8E3fvVV7K2WYvcrIWi1yVtl5alegPT0cX18DJsEy2ENpZsGbLMcIPWoeEyctSmLs7RrkuyQomY0tz5gSFPIyZMwVxqbCysos5JNEc4t_wt7JTz0r0HIpj1BYWVvoAorMikdJLHVikb04LbAPb7ytaLhlBDC48REqGSAD53ta9tS1GOmTL-6HqpnCvtm01js-lIBnDcC3cv-q_YYdeMuu2elV4pUwAf-8e-Y2F1mtLN72sZb715_EMfk0F8jSg2gHeNZvTfEiG1fxpHAcgNnekFkNh780l587sm-OaJxPzJAXzqtGvt07d_cf_xXzyA51GTwyOk7BB2lnf37oNHUsvsqO4uR7B7PhoMxv48uBhPfvi7w2Toj1dC_QVcSSPg |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-N7mG8IL7JGGCkbQ9oYXbsxAkSQnxs6thWVaid9mYcx4FJKO3WTqj_FH8jvny1pWhve4qinKPEdz7_zvb9DmBb0zi1wuR-rnG1KhGJ70Cs9anWCaW5NVmOC_qnvag7FF_Pw_M1-NPkwuCxysYnlo46GxlcI99nSHTuwG_MPowvfawahburTQmNyiyO7ey3C9km74--OP3uBMHhweBz16-rCvgmlGzqs1RzjaGQ5jKw1CQ2zDCIidI8FiGlmXWjIEsCJnTObKJNKExMrZWIvTk33L33DqwL7kKZDqx_Ouj1vzW-nzu0hICbRRIjs5jXGYGUx_t6jOzgjL_FAjYbzrcVPy7d7LQ8H66A3NWzmv9s2Jbz4OF9uFcDWPKxsrgHsGaLh7DbrxiwZ3tkME_omuyRXdKfc2PPHsHZcDGZhrgLqc6i451BC7wiSC1NcENh8o4spIeRi4XD72VL0xSCmTyG4a0o4Ql0ilFhnwERzLiGwkjXQORGpFJayUMTxyakOTcebLadrcYVhYcSDpVEIo48eNP0vjI1KTrW5vilys15HiunNoVqU4H0YLsVbl70X7GtRo2qdggTNTdfD163j91Qxu7UhR1dlzIuXnSIi94kg4gecbMHTyvLaL8lwGICSRh4IJdsphVAKvHlJ8XFz5JSnEcSKzZ7sNNY18Knr_7i5s2_-Ao2uoPTE3Vy1Dt-DneDqoKIT9kWdKZX1_aFw3HT9GU9eAh8v-3x-hesHVwo |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NIQEviG8yBhhp2wNaqB07sYOEEGJUG4OpDyvqm3EcByahtFs7of5r_HX48tWWor3tKYp8jhzfnf07-z4AdgxVmRO2CAuDp1WpSEMPYl1IjUkpLZzNCzzQ_3qSHA7F51E82oA_bSwMulW2a2K1UOdji2fkPYaJzj34VaxXNG4Rg4P--8l5iBWk8Ka1LadRi8ixm__25tv03dGB5_VuFPU_nX48DJsKA6GNJZuFLDPcoFlkuIwctamLczRokqxQIqY0d14j8jRiwhTMpcbGwirqnEQczrnl_rs34KbkMUMdk6PO2OMeNyH0ZolEG03xJjaQctUzE8wTzvgbLGVz269y5Y9zv0-t7oxrcHfda_Ofq9tqR-zfg7sNlCUfatm7DxuufAB7gzoX9nyfnC5Cu6b7ZI8MFlmy5w_h23A5rIb4B6m90vHNoixeEEwyTfBqYfqWLAWKkbMlN_iqp21LwkwfwfBaWPAYNstx6Z4CEcz6jsJK30EUVmRSOs8aq5SNacFtAFvdZOtJncxDC49PEqGSAF63s69tkx4dq3T80tU1PVfas00j23QkA9jpiNsP_Zdsu2WjbpaGqV4IcgCvumav1DidpnTjy4rGW44ee9GraBDbI4IO4EktGd1YIiwrkMZRAHJFZjoCTCq-2lKe_aySi_NEYu3mAHZb6Voa-vovbl39iy_hltdS_eXo5PgZ3InqUiIhZduwObu4dM89oJtlLyrNIfD9ulX1L_JkXvg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Understanding+and+targeting+cancer+stem+cells%3A+therapeutic+implications+and+challenges&rft.jtitle=Acta+pharmacologica+Sinica&rft.au=Chen%2C+Ke&rft.au=Huang%2C+Ying-hui&rft.au=Chen%2C+Ji-long&rft.date=2013-06-01&rft.pub=Nature+Publishing+Group&rft.issn=1671-4083&rft.eissn=1745-7254&rft.volume=34&rft.issue=6&rft.spage=732&rft_id=info:doi/10.1038%2Faps.2013.27&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=2987775981 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F95561A%2F95561A.jpg |